J. Goldman & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

J. Goldman & Co’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,045	Closed	-$465K	–	625
2025 Q2	$465K	Buy	+1,045	New	+$482K	0.01%	385
2024 Q2	–	Sell	-4,236	Closed	-$1.77M	–	605
2024 Q1	$1.77M	Buy	+4,236	New	+$1.79M	0.06%	230
2023 Q3	–	Sell	-1,750	Closed	-$616K	–	493
2023 Q2	$616K	Buy	+1,750	New	+$590K	0.02%	280
2023 Q1	–	Sell	-30,168	Closed	-$8.71M	–	493
2022 Q4	$8.71M	Buy	+30,168	New	+$9.19M	0.43%	71
2022 Q2	–	Sell	-11,970	Closed	-$3.12M	–	478
2022 Q1	$3.12M	Buy	11,970 +6,708	+127%	+$1.59M	0.14%	169
2021 Q4	$1.16M	Buy	+5,262	New	+$1.02M	0.06%	248
2021 Q2	–	Sell	-29,508	Closed	-$6.34M	–	527
2021 Q1	$6.34M	Buy	+29,508	New	+$6.48M	0.2%	128
2017 Q3	–	Sell	-23,500	Closed	-$3.03M	–	412
2017 Q2	$3.03M	Buy	+23,500	New	+$2.83M	0.16%	144

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

J. Goldman & Co's VRTX Position: Q3 2025 in Review

J. Goldman & Co sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 1,045 shares — an estimated $465K sold.

J. Goldman & Co first reported a position in VRTX in Q2 2017 and held it in 8 quarters. The position peaked at $8.71M in Q4 2022. 1,519 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

J. Goldman & Co reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
J. Goldman & Co sold 1,045 Vertex Pharmaceuticals shares in Q3 2025, an estimated $465K.
J. Goldman & Co first reported a position in Vertex Pharmaceuticals in Q2 2017 and held it in 8 quarters.
J. Goldman & Co's Vertex Pharmaceuticals position peaked at $8.71M in Q4 2022.
1,519 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on J. Goldman & Co's 13F filing for Q3 2025, filed 14 Nov 2025.